This Folate deficiency anemia Drug Market research report is formulated by using integrated advancements and latest technology to obtain the most excellent results. It becomes easy to create sustainable and profitable business strategies by using valuable and actionable market insights included in this Folate deficiency anemia Drug report. This market research report encompasses various parameters of the market. These parameters range from industry outlook, currency and pricing, value chain analysis, market overview, premium insights, key insights to the company profile of the key market players. A complete overview of the ABC industry has been offered via this report which considers various aspects of product definition, market segmentation, and the existing retailer landscape.
Global Folate deficiency anemia Drug Market is rising gradually with a substantial CAGR in the forecast period of 2019-2026. Government policies and initiatives to offer a fund to many research institute and pharmaceuticals companies for developing novel therapy and emergence of drugs used in the treatment of Crohn’s disease, celiac disease, certain types of cancer and kidney problem that required dialysis as these can cause folate deficiencies are the key factors for the growth of this market
Folate deficiency anemia is also knowns as Vitamin B9 deficiency anemia. It occurs when lack of lack of vitamin B12 causes the body to produce insufficient or abnormally large red blood cells which ultimately affects the body to be functional. Folate plays an important in the synthesis of genetic material like DNA, RNA and proteins. This deficiency may defacement cell division and an accumulation of possibly toxic metabolites, e.g. homocysteine. It is also important for re regulating the manufacture of red blood cells. It is most commonly found in pregnant and lactating women.
According to the article published in the National Health Services, it is estimated 1 in every 20 people aged 65 to 74 years old and 1 in every 10 people aged 75 or over are living with both vitamin B12 deficiency and folate deficiency anemia. This growing prevalence of folate deficiency anemia worldwide and vulnerable lactating women population are the key factors for the growth of this market.
Key Market Players: GlaxoSmithKline plc, Eli Lilly and Company, Merck KGaA, bluebird bio, Inc, Biocon, GlycoMimetics, Regen BioPharma Inc, Bayer AG, Acceleron Pharma, Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc, Merck & Co., Inc, Novartis AG, Teva Pharmaceutical Industries Ltd., AMAG Pharmaceuticals, Akebia Therapeutics, Vifor Pharma Management Ltd, Omeros Corporation, PHARMACOSMOS A/S, Helsinn Healthcare SA, and many others.
Download Sample Copy of Report @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-folate-deficiency-anemia-drug-market
- Prevalence of inflammatory bowel disease worldwide acts as a driver for this market
- Increase cases of kidney disorders where dialysis is predominant treatment also enhances the market growth
- Increase in the rate of research and development initiatives is driving folate deficiency anemia therapeutics market
- Strategic alliance between the companies to increase the availability of the products is also driving the market growth
Segmentation: Global Folate Deficiency Anemia Drug Market
- Dietary Folate Deficiency Anemia
- Drug-Induced Folate Deficiency Anemia
- Unspecified Folate Deficiency Anemia
By Treatment Type
- Dietary Supplements
By Drug Type
- Vitamin B12 Injections
- Iron Deficiency Replacement Drugs
By Route of Administration
- Specialty Clinics
- North America
- South America
- Middle East & Africa
Key Developments in the Market:
- In April 2019, Merck KGaA has launched Arcofolin, a monosodium salt of L-5-methyltetrahydrofolic acid for the treatment and prevention from the folate deficiencies. The launch of Arcofolin will give patients a new biologic form of vitamin B9 which is not only easy for the body to metabolize but also enhanced the water solubility and hence improved condition of folate deficiencies
- In January 2015, Helsinn Healthcare SA In-licensed exclusive U.S. commercialization rights from PHARMACOSMOS A/S for Monofer, an intravenous iron replacement therapy to be developed for the treatment of iron deficiency anaemia. Under the deal terms, PHARMACOSMOS A/S to receive a payments of up to USD 130.00mm for Monofer and eligible to receive further payments for the manufacture and supply of Monofer to Helsinn Healthcare SA in the United States. These strategic alliances between the companies increase availability of the product for patients suffering from folate deficiency anaemia throughout the United States
Global folate deficiency anemia drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global folate deficiency anemia drug market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Customization with 25% Discount Available on This Report @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-folate-deficiency-anemia-drug-market
Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing [email protected] . We are content with our glorious 99.9 % client satisfying rate.
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725